What to expect, month by month

The most common reason people abandon this treatment is not side effects. It is a timeline nobody explained — a first month that feels like nothing, judged against expectations set by trial headlines describing a year.

What follows is the usual shape. Individual experience varies enormously, and the point of describing an average is to give you something to be different from, not a target to hit.

Weeks 1–4: nothing much, and that is correct

You are on a starting dose chosen for tolerance rather than effect, and you are not yet receiving all of even that dose, because blood levels are still climbing toward their plateau. Semaglutide takes four to five weeks to reach steady state; tirzepatide about 25 days.

What people usually notice: mild early fullness, some nausea in the days after the injection, and — for some — the first hint that the constant background hum of thinking about food has quietened.

What it does not mean: that the medicine is or is not going to work. There is no information available yet.

Weeks 5–12: the first real doses

This is where most people first notice something unmistakable. Portions that were normal become too much. Meals get left unfinished without a decision having been made. Many describe the change less as willpower and more as an absence — the pull toward a second helping is simply not there.

Side effects usually peak here too, because each increase produces its own wave, and you are climbing. The pattern is consistent: quiet for a few days after an increase, worst around days three to seven, easier in week two, settled by weeks three and four. The shape is described here.

Weight typically starts moving in a way that is visible above the noise. Half a kilogram a week is a good result and is smaller than daily fluctuation — which is why only the four-week trend means anything.

Months 4–6: the working phase

By now you are usually at or near a maintenance dose, side effects have settled into something predictable, and the routine has become routine.

Two things tend to happen in this window that people are not warned about.

The first plateau. Almost everyone has a stretch where the number stops moving, and almost everyone reads it as failure. Most are not plateaus at all — they are normal fluctuation, water shifts after a dose change, or composition changing under a stable number. Telling the difference is here.

Appetite partially returning. Not to baseline, but the extreme suppression of the early months often softens. Portions creep back up without a decision, and intake drifts. This is the point at which the habits built earlier either hold or do not.

Months 7–12: flattening

Weight loss slows, and this is expected physiology rather than a failure. A smaller body costs less to run, so the deficit that produced the first ten kilograms does not exist any more at the new weight. In the major trials the curve flattens across this period and approaches a plateau by around the one-year mark.

This is also where the conversation shifts from losing to maintaining, and where it is worth asking your prescriber directly what the plan is — because maintenance is a legitimate endpoint that most people arrive at without ever having decided on it.

What the numbers actually say

Trial averages for this class differ by molecule and by dose, and they are reported over roughly a year alongside lifestyle support. Two honest caveats matter more than the figures themselves.

First, the spread within any trial arm is very wide. Substantial numbers of participants lose far more than the average and substantial numbers lose far less. An average is the worst possible predictor of an individual.

Second, trial participants receive structured dietary and activity support alongside the medicine. Results without that support are not the same results.

What is worth tracking, and what is noise

• Weight as a four-week trend. A single reading tells you about hydration, not fat.
• Waist circumference. The single most informative addition to the scale, and the one people skip.
• Protein intake. The variable most likely to be quietly failing, and the one with the longest consequences.
• Which rung you are on, and when it started. The thing people most often cannot answer at an appointment.
• How clothes fit. Unfashionable and remarkably good at detecting composition change the scale hides.

Things that are normal and alarm people anyway

• A week of no change, or a week of gain, in the middle of steady loss.
• Losing quickly at first, then slowing — this is the expected shape.
• Feeling nothing on the starting dose.
• Appetite returning somewhat after the first few months.
• Hair shedding a few months in — usually the aftermath of rapid loss rather than the drug.

Things that are worth raising

• Side effects that have not settled by the fourth week at a dose.
• No change at all in appetite after two months at a genuine treatment dose.
• Severe abdominal pain, persistent vomiting, or an inability to keep fluids down — none of which is an adjustment symptom.
• Losing weight very fast. Faster is not better; it costs more muscle.

Related

• How GLP-1 medicines actually work — Not appetite suppressants, not fat burners. They are copies of a gut hormone your body already makes — which explains almost everything.
• How long GLP-1 medicines stay in your system — Half-lives, steady state, and the arithmetic behind a missed dose — including why stopping does not mean the effect ends that week.

Which medicine you are on

Everything above applies across the class, because it comes from a shared mechanism. The numbers that differ — dose ladders, missed-dose windows, in-use storage periods, half-lives — differ by product, sometimes substantially. Each medicine has its own reference here:

Ozempic · Wegovy · Mounjaro · Zepbound · Rybelsus · Saxenda · Victoza · Trulicity · all medicines